摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-((2R,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide | 35301-25-8

中文名称
——
中文别名
——
英文名称
N-((2R,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide
英文别名
N-((1R,2R)-2-hydroxy-1-hydroxymethyl-heptadecyl)-acetamide;LS-threo-2-Acetylamino-octadecan-1,3-diol;N-((1R,2R)-2-Hydroxy-1-hydroxymethyl-heptadecyl)-acetamid;N-[(2R,3R)-1,3-dihydroxyoctadecan-2-yl]acetamide
N-((2R,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide化学式
CAS
35301-25-8
化学式
C20H41NO3
mdl
——
分子量
343.55
InChiKey
CRJGESKKUOMBCT-WOJBJXKFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    24
  • 可旋转键数:
    17
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    69.6
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Development of Asymmetric Transfer Hydrogenation with a Bifunctional Oxo-Tethered Ruthenium Catalyst in Flow for the Synthesis of a Ceramide (<scp>d</scp>-<i>erythro</i>-CER[NDS])
    作者:Taichiro Touge、Masahiro Kuwana、Yasuhiro Komatsuki、Shigeru Tanaka、Hideki Nara、Kazuhiko Matsumura、Noboru Sayo、Yoshinobu Kashibuchi、Takao Saito
    DOI:10.1021/acs.oprd.8b00338
    日期:2019.4.19
    development of an efficient synthetic route for an optically active ceramide compound (d-erythro-CER[NDS]) is described. The route proceeds through asymmetric transfer hydrogenation in a pipes-in-series flow reactor with oxo-tethered ruthenium complex-catalyzed dynamic kinetic resolution. This synthesis was accomplished without any expensive reagents, and none of the intermediates required isolation
    一种有效的合成路线的用于光学活性的神经酰胺化合物的开发(d -赤-CER [NDS])进行说明。该路线是在串联的管式反应器中通过不对称转移氢化进行的,该串联反应器具有羰基连接的络合物催化的动态动力学拆分。该合成无需任何昂贵的试剂即可完成,并且无需分离任何中间体。这导致了一个健壮的过程,并已成功地在生产规模上运行。
  • Sticht et al., 1972, vol. 8, p. 10,17,22
    作者:Sticht et al.
    DOI:——
    日期:——
  • Molecular Interactions and Functional Interference between Vitronectin and Transforming Growth Factor-β
    作者:Michael Schoppet、Triantafyllos Chavakis、Nadia Al-Fakhri、Sandip M Kanse、Klaus T Preissner
    DOI:10.1038/labinvest.3780393
    日期:2002.1
    Different extracellular matrix proteins have been described as binding proteins for growth factors, influencing their storage or presentation towards cellular receptors. The multifunctional adhesive glycoprotein vitronectin (VN), which is found in the circulation and widely distributed throughout different tissues, has been implicated in the regulation of vascular cell functions, and these activities could be related to interactions with various growth factors. In vitro, soluble VN interfered with transforming growth factor-beta (TGF-beta) binding to isolated extracellular matrix and was found to associate with TGF-beta1 and TGF-beta2 as well as with other growth factors such as vascular endothelial growth factor, epidermal growth factor, or basic fibroblast growth factor in a saturable manner. In particular, binding of TGF-beta was maximal for the heparin-binding multimeric isoform of VN, whereas VN in a ternary complex with thrombin and antithrombin or plasma VN exhibited weaker binding. Plasminogen activator inhibitor-1 (PAI-1) or heparin, but not desulfated glycosaminoglycans, interfered with binding of VN to TGF-beta, and soluble PAI-1 was able to dissociate VN-bound TGF-beta. Upon limited plasmin proteolysis of VN, only the fragments comprising the intact aminoterminal portion of VN bound to TGF-beta as did a synthetic peptide (amino acids 43 to 62), indicating that TGF-beta and PAI-1 share common binding site(s) on VN. Although VN did not influence TGF-beta bioactivity for mink lung epithelial cells, TGF-beta dose dependently inhibited both urokinase-receptor as well as alpha(v)-integrin-dependent adhesion to VN. This activity of TGF-beta was reminiscent of the antiadhesive function of PAI-1. In atherosclerotic tissue sections, staining patterns of VN and TGF-beta indicated their colocalization. These findings describe VN as a new binding protein for TGF-beta, whereby specific functions of both factors become modulated by this interaction.
查看更多

同类化合物

鞘磷酯 鞘氨醇半乳糖苷-3'-硫酸酯 西高苷 西地芬戈 葡糖鞘氨醇半乳糖苷 葡糖基-N-(2-羟基十八碳酰基)二氢鞘氨醇 脑苷脂类 脑苷脂D 脑苷脂 B 红细胞糖苷酯 神经鞘氨醇半乳糖苷 神经酸酰胺 神经酰胺N-甲基氨基乙基膦酸酯 神经酰胺 神经节苷酯Gm3内酯 神经节苷酯GM1(牛脑) 神经节苷脂GM3 神经节苷脂 溶血神经酰胺三己糖苷 正二十四烷基二氢-葡糖脑苷脂 己酰神经鞘氨醇 大豆脑苷 I 双唾液酸神经节苷酯GD1A 双唾液酸神经节苷脂GD2 单唾液酸神经节苷酯 单唾液酸神经节苷脂GM2 十四酰鞘氨醇 人脾脏葡糖苷酰鞘氨醇 二羟基神经酰胺 二十二烷酰胺,N-[1-[(b-D-吡喃葡萄糖氧基)甲基]-2,3-二羟基-5-十七碳烯基]-2-羟基-(9CI) 二十二烷酰胺,N-[(1S,2R,3E,7E,9E)-1-[(b-D-吡喃葡萄糖氧基)甲基]-2-羟基-8-甲基-3,7,9-十七碳三烯-1-基]-2-羟基-,(2R)- 二十二烷酰胺,N-[(1S,2R,3E)-2-羟基-1-(羟甲基)-3-十五碳烯基]- 乳酰基-N-脂酰基鞘氨醇(牛) 乳糖酰基鞘糖脂 乳糖酰基鞘氨醇 β-D-葡萄糖基C4-神经酰胺 alpha-半乳糖基-C16-神经酰胺 [(E,2S,3R)-3-羟基-2-[[(Z)-十八碳-9-烯酰基]氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(E,2S,3R)-3-羟基-2-[[(Z)-3-芘-1-基丙-2-烯酰基]氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(E,2S,3R)-3-羟基-2-[11-(芘-1-基磺酰基氨基)十一烷酰基氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(E)-2-二甲基氨基-3-羟基十八碳-4-烯基]磷酸二氢酯 [(2R,3S,4S,5R,6R)-3,5-二羟基-2-(羟基甲基)-6-[(E,2S,3R)-3-羟基-2-(二十四烷酰基氨基)十八碳-4-烯氧基]四氢吡喃-4-基]氢硫酸盐 TNPAL-鞘磷脂 O-甘露糖基-(1-3)-O-甘露糖基-(1-4)-O-吡喃葡萄糖基-(1-1)-2-N-二十四烷酰基鞘氨醇 N-(NBD-氨基脲酰)沙丁胺醇 N-辛酰基神经酰胺-1-磷酸酯(铵盐) N-辛酰基4-羟基鞘氨醇(酿酒酵母) N-辛酰基-D-神经鞘氨醇 N-肉豆蔻酰-D-赤型-鞘氨醇 N-肉豆蔻酰-D-赤-鞘氨醇